<span id="midArticle_start"/>A U.S. district court has ruled that Amarin Corp's fish oil pill, Vascepa, is eligible for five years of marketing exclusivity, setting aside a U.S. Food and Drug administration decision.
<span id="midArticle_0"/>Amarin's shares rose as much as 44 percent to $2.80 on the Nasdaq. The stock was trading up 19 percent at $2.33 on Thursday afternoon.
<span id="midArticle_1"/> <span class="first-article-divide"/>Vascepa was approved in 2012 to reduce high levels of blood fat called triglycerides in patients not using cholesterol-lowering statins.
<span id="midArticle_2"/> <span class="second-article-divide"/>
<span id="midArticle_3"/> <span class="third-article-divide"/> (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Don Sebastian)
<span id="midArticle_4"/>
<span id="midArticle_0"/>Amarin's shares rose as much as 44 percent to $2.80 on the Nasdaq. The stock was trading up 19 percent at $2.33 on Thursday afternoon.
<span id="midArticle_1"/> <span class="first-article-divide"/>Vascepa was approved in 2012 to reduce high levels of blood fat called triglycerides in patients not using cholesterol-lowering statins.
<span id="midArticle_2"/> <span class="second-article-divide"/>
<span id="midArticle_3"/> <span class="third-article-divide"/> (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Don Sebastian)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1Hz3j3M
No comments:
Post a Comment